Status:
COMPLETED
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
Lead Sponsor:
University of Zagreb
Conditions:
Coronary Artery Disease
Aspirin Resistance
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Reactive platelet hyperactivity following coronary artery bypass grafting (CABG) might lead to thrombotic complications and major ischemic cardiac events. The aim of this study is to evaluate the chan...
Eligibility Criteria
Inclusion
- Isolated coronary artery bypass grafting
- Patients older than 18 years
- Written informed consent
- Accurate antiplatelet therapy administration documentation
Exclusion
- Missing consent
- Patients with cardiac surgical procedures other than isolated CABG
- Antiplatelet therapy other than aspirin 300 mg after CABG
- Previous PCI requiring clopidogrel therapy after CABG
- Patients with unknown preoperative anti-platelet status
- Urgent or emergent surgery
- Off-pump CABG
- Re-Do CABG
- Patients younger than 18 years
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01159639
Start Date
June 1 2010
End Date
February 1 2013
Last Update
August 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical school Zagreb, University hospital center Zagreb
Zagreb, Croatia, Croatia, 10000